

Geoffrey J Gorse

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9363706/publications.pdf>

Version: 2024-02-01

43
papers

2,157
citations

257450

24
h-index

265206

42
g-index

43
all docs

43
docs citations

43
times ranked

2649
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized, Double-blind Controlled Phase 3 Trial Comparing the Immunogenicity of High-Dose and Standard-Dose Influenza Vaccine in Adults 65 Years of Age and Older. <i>Journal of Infectious Diseases</i> , 2009, 200, 172-180.	4.0	334
2	Prevalence of Antibodies to Four Human Coronaviruses Is Lower in Nasal Secretions than in Serum. <i>Vaccine Journal</i> , 2010, 17, 1875-1880.	3.1	170
3	Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. <i>Aids</i> , 1998, 12, 2407-2415.	2.2	151
4	Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus-associated illnesses. <i>Journal of Medical Virology</i> , 2020, 92, 512-517.	5.0	129
5	Safety and immunogenicity of varying dosages of trivalent inactivated influenza vaccine administered by needle-free jet injectors. <i>Vaccine</i> , 2001, 19, 4703-4709.	3.8	109
6	Human Coronavirus and Acute Respiratory Illness in Older Adults with Chronic Obstructive Pulmonary Disease. <i>Journal of Infectious Diseases</i> , 2009, 199, 847-857.	4.0	102
7	Increased Anti-Influenza A Virus Cytotoxic T Cell Activity following Vaccination of the Chronically Ill Elderly with Live Attenuated or Inactivated Influenza Virus Vaccine. <i>Journal of Infectious Diseases</i> , 1995, 172, 1-10.	4.0	90
8	Safety and Immunogenicity of a High-Titered Canarypox Vaccine in Combination With rgp120 in a Diverse Population of HIV-1-Uninfected Adults: AIDS Vaccine Evaluation Group Protocol O22A. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 29, 254-261.	2.1	88
9	Cytotoxic T Cell and Neutralizing Antibody Responses to Human Immunodeficiency Virus Type 1 Envelope with a Combination Vaccine Regimen. <i>Journal of Infectious Diseases</i> , 1998, 177, 301-309.	4.0	75
10	Induction of Mucosal Antibodies by Live Attenuated and Inactivated Influenza Virus Vaccines in the Chronically Ill Elderly. <i>Journal of Infectious Diseases</i> , 1996, 173, 285-290.	4.0	70
11	Immunogenicity and safety of Fluzone® intradermal and high-dose influenza vaccines in older adults ≥65 years of age: A randomized, controlled, phase II trial. <i>Vaccine</i> , 2014, 32, 2507-2517.	3.8	68
12	Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. <i>Vaccine</i> , 2003, 21, 2133-2144.	3.8	62
13	Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. <i>Vaccine</i> , 2008, 26, 215-223.	3.8	53
14	Safety and Immunogenicity of a High-Titered Canarypox Vaccine in Combination With rgp120 in a Diverse Population of HIV-1-Uninfected Adults: AIDS Vaccine Evaluation Group Protocol O22A. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 29, 254-261.	2.1	52
15	Immunity to Influenza in Older Adults with Chronic Obstructive Pulmonary Disease. <i>Journal of Infectious Diseases</i> , 2004, 190, 11-19.	4.0	52
16	Recognizing Influenza in Older Patients with Chronic Obstructive Pulmonary Disease Who Have Received Influenza Vaccine. <i>Clinical Infectious Diseases</i> , 2003, 36, 169-174.	5.8	47
17	Impact of a Winter Respiratory Virus Season on Patients With COPD and Association With Influenza Vaccination. <i>Chest</i> , 2006, 130, 1109-1116.	0.8	45
18	Superiority of Live Attenuated Compared with Inactivated Influenza A Virus Vaccines in Older, Chronically Ill Adults. <i>Chest</i> , 1991, 100, 977-984.	0.8	44

#	ARTICLE	IF	CITATIONS
19	HIV-1MN Recombinant Glycoprotein 160 Vaccine-Induced Cellular and Humoral Immunity Boosted by HIV-1MN Recombinant Glycoprotein 120 Vaccine. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 115-132.	1.1	43
20	Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant GP160. <i>Vaccine</i> , 1992, 10, 383-388.	3.8	36
21	Influenza Virus Vaccination of Patients With Chronic Lung Disease. <i>Chest</i> , 1997, 112, 1221-1233.	0.8	34
22	Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age. <i>Vaccine</i> , 2013, 31, 2358-2365.	3.8	33
23	Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults. <i>Vaccine</i> , 2015, 33, 1151-1159.	3.8	32
24	Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. <i>Vaccine</i> , 1998, 16, 493-506.	3.8	28
25	Enhanced lymphoproliferation to influenza a virus following vaccination of older, chronically ill adults with live-attenuated viruses. <i>Scandinavian Journal of Infectious Diseases</i> , 1991, 23, 7-17.	1.5	26
26	HIV Type 1 Vaccine-Induced T Cell Memory and Cytotoxic T Lymphocyte Responses in HIV Type 1-Uninfected Volunteers. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1175-1189.	1.1	24
27	DNA and Modified Vaccinia Virus Ankara Vaccines Encoding Multiple Cytotoxic and Helper T-Lymphocyte Epitopes of Human Immunodeficiency Virus Type 1 (HIV-1) Are Safe but Weakly Immunogenic in HIV-1-Uninfected, Vaccinia Virus-Naive Adults. <i>Vaccine Journal</i> , 2012, 19, 649-658.	3.1	22
28	Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. <i>Vaccine</i> , 1994, 12, 912-918.	3.8	17
29	MN and IIIB Recombinant Glycoprotein 120 Vaccine-Induced Binding Antibodies to Native Envelope Glycoprotein of Human Immunodeficiency Virus Type 1 Primary Isolates. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 921-930.	1.1	17
30	Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age. <i>Vaccine</i> , 2013, 31, 6034-6040.	3.8	17
31	Coronavirus and Other Respiratory Illnesses Comparing Older with Young Adults. <i>American Journal of Medicine</i> , 2015, 128, 1251.e11-1251.e20.	1.5	17
32	Cytokine responses to human immunodeficiency virus type 1 (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1SF-2 recombinant GP120. <i>Vaccine</i> , 2001, 19, 1806-1819.	3.8	12
33	Recombinant gp160 vaccination schedule and MHC HLA type as factors influencing cellular responses to HIV-1 envelope glycoprotein. <i>Vaccine</i> , 1995, 13, 1170-1179.	3.8	11
34	Cellular Immune Responses in Asymptomatic Human Immunodeficiency Virus Type 1 (HIV-1) Infection and Effects of Vaccination with Recombinant Envelope Glycoprotein of HIV-1. <i>Vaccine Journal</i> , 2006, 13, 26-32.	3.1	10
35	Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants. <i>Vaccine Journal</i> , 2014, 21, 1589-1599.	3.1	10
36	Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies. <i>Vaccine</i> , 1999, 18, 835-849.	3.8	9

#	ARTICLE	IF	CITATIONS
37	Interpatient mutational spectrum of human coronavirusâ€œOC43 revealed by illumina sequencing. Journal of Medical Virology, 2017, 89, 1330-1338.	5.0	6
38	A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery system. Vaccine, 2022, 40, 1271-1271.	3.8	5
39	Outpatient healthcare personnel knowledge and attitudes towards infection prevention measures for protection from respiratory infections. American Journal of Infection Control, 2021, 49, 1369-1375.	2.3	3
40	Binding of antibodies to human immunodeficiency virus type 1 (HIV-1)-infected lymphocytes elicited by vaccines and by natural infection. Vaccine, 2004, 22, 383-397.	3.8	2
41	Influence of Preseason Antibodies Against Influenza Virus on Risk of Influenza Infection Among Healthcare Personnel. Journal of Infectious Diseases, 2022, 225, 891-902.	4.0	1
42	MAS-1, a novel water-in-oil adjuvant/delivery system, with reduced seasonal influenza vaccine hemagglutinin dose may enhance potency, durability and cross-reactivity of antibody responses in the elderly. Vaccine, 2022, 40, 1472-1472.	3.8	1
43	1054Immunogenicity And Safety of Quadrivalent Influenza Vaccine Administered Intradermally (ID) in Adults 18 through 64 Years of Age. Open Forum Infectious Diseases, 2014, 1, S309-S309.	0.9	0